View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
February 5, 2020

AskBio initiates Phase I trial of gene therapy for heart failure

Asklepios BioPharmaceutical (AskBio) and its subsidiary NanoCor Therapeutics have dosed the first patient in a Phase I clinical trial of gene therapy candidate NAN-101 to treat congestive heart failure.

Asklepios BioPharmaceutical (AskBio) and its subsidiary NanoCor Therapeutics have dosed the first patient in a Phase I clinical trial of gene therapy candidate NAN-101 to treat congestive heart failure.

Congestive heart failure is characterised by the inability of the heart to supply the necessary blood and oxygen to the body. The condition lacks cure, while drugs and surgical therapy are intended to alleviate symptoms and slow damage.

NAN-101 is an adeno-associated virus (AAV) gene therapy designed to stimulate protein phosphatase inhibitor 1 (I-1c) to block the action of protein phosphatase 1 (PP1), which is linked to heart failure.

The medication is directly given to the heart via an intracoronary infusion.

The NAN-CS101 open-label, dose-escalation, multi-centre trial will evaluate three doses of the gene therapy in approximately 12 patients with NYHA Class III heart failure.

The primary objective of the study is safety, along with the effect of NAN-101 on patient health, which is tracked as changes in exercise capacity, heart function, and quality of life.

AskBio chief scientific officer and co-founder Jude Samulski said: “Dosing the first patient using gene therapy to target I-1c to improve heart function is a tremendous milestone not only for the AskBio and NanoCor teams but, more importantly, for patients whose quality of life is negatively affected by CHF.

“We initially developed this gene therapy as treatment for late-stage Duchenne muscular dystrophy patients who typically die from cardiomyopathy. Following preclinical studies, we observed that heart function improved, which led us to investigate treatment for all types of heart failure.”

The Phase I trial is expected to be completed in July next year.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena